New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer:

Experimental arm: apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor, plus degarelix, a hormonal therapy used to reduce testosterone
Experimental arm: apalutamide and degarelix plus abiraterone acetate and prednisone
Control arm: degarelix alone

“Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer,” according to findings from the phase 3 SPARTAN trial reported in OncLive on Feb. 5. The SPARTAN trial, published in the New England Journal of Medicine on Feb. 8, found that “median metastasis-free survival was more than 2 years longer” for men who received apalutamide. Read more in the New York Times.

Brendan Curti, M.D., the principal investigator of the new three-arm study at Providence Cancer Institute, is a medical oncologist and director of genitourinary oncology research at the Earle A. Chiles Research Institute.

See Providence study details here:

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

More prostate cancer studies

This study is one of three clinical trials open to men with prostate cancer at Providence Cancer Institute. See all prostate cancer studies.

To refer patients to any of these studies, call Providence Cancer Institute’s Clinical Research office at 503-215-2614 or visit oregon.providence.org/clinical-trials.

Welcome to your journey for creating a healthier you

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

Most Recent Articles

Providence Alaska Medical Center (PAMC) has been recognized by U.S. News & World Report for providing Alaskans with high-quality care, especially to patients in underserved communities.

Providence will be collaborating with Rockport’s Granada Rehabilitation and Wellness Center in Eureka to deliver rehabilitation services in Humboldt County starting on November 18.

"Within Reach: The Fight to Finish Cancer" follows patient participants and teams of researchers and clinicians at Providence Cancer Institute working to create a living drug for incurable cancers.

Providence registered dietitian Christina Speaks, MS, RDN, LD, shares valuable information about food and common cancer myths.

A new type of surgical treatment for patients with benign prostatic hyperplasia (BPH) uses the power of water delivered with robotic precision to provide long-lasting BPH relief

Providence honors the donors who have given the gift of life, health and hope to those in need.

Providence honors the donors who have given the gift of life, health and hope to those in need.

Providence honors the donors who have given the gift of life, health and hope to those in need.

Providence honors the donors who have given the gift of life, health and hope to those in need.

Introducing Moxi — Providence Saint John’s newest hospital assistant. Moxi is a collaborative robot that helps caregivers with daily tasks so they can focus on what they do best: caring for you.

Michelle Hook, MSN, RN, NE-BC, has been named chief nursing officer at Providence Saint Joseph Medical Center

In 2023, Providence Alaska provided $67,000 to the Valdez Food Bank to help fund meal-delivery services for older adults and provide emergency financial assistance to low-income families.

A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

“For my patients.” “For my friend’s daughter.” “For the challenge.” “For the cure.” Providence runners and walkers share why they’re doing the relay – and helping raise funds to #FINISHCANCER.

Providence Alaska Medical Center has received four American Heart Association Get With The Guidelines and Mission: Lifeline achievement awards for the treatment of heart disease and stroke.

Cancer survivor Mark Williams chats with Dr. Brendan Curti about

Providence Saint Joseph Medical Center has been named one of America’s Best Neurological Hospitals and America’s Best Orthopedic Hospitals for 2024 by Newsweek and Statista Inc.

U.S. News & World Report recently recognized Providence Santa Rosa Memorial Hospital and Petaluma Valley Hospital with the highest distinction a hospital can earn for cardiac care.